aTyr Pharma's lung disease drug misses main goal in late-stage trial
15/09/2025 12:37
Sept 15 (Reuters) - aTyr Pharma ATYR.O said on Monday its experimental drug did not meet the main goal in a late-stage study in patients with a type of lung disease known as pulmonary sarcoidosis. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Pooja Desai) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan